The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass

Rusch, Valerie W.; Baldini, Elizabeth H.; Bueno, Raphael; Perrot, Marc de; Flores, Raja M.; Hasegawa, Seiki; Klepetko, Walter; Krug, Lee M.; Lang-Lazdunski, Loı̈c; Pass, Harvey I.; Weder, Walter; Sugarbaker, David J.

doi:10.1016/j.jtcvs.2013.01.039

Cited by 145 publications

(108 citation statements)

References 4 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Following a long discussion in multiple forums at the IMIG meeting in 2012, with the main emphasis on surgical input, an agreement was obtained between the attendees on several key issues concerning the treatment of MPM and these are summarised in table 2 [12].…”

Section: Summary Of Current Guidelinesmentioning

confidence: 99%

“…For this reason, newer treatment modalities are currently being explored, mostly consisting of multimodality therapy comprising chemotherapy, radiotherapy and surgery [12,13]. The precise role and type of surgery remain highly controversial and no precise guidelines are currently available due to the lack of large randomised controlled trials [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multimodal management of malignant pleural mesothelioma: where are we today?

Schil

Opitz²,

Weder³

et al. 2014

European Respiratory Journal

View full text Add to dashboard Cite

The prognosis of patients with malignant pleural mesothelioma remains poor and although it is clear that multimodal therapy is necessary to improve long-term results, precise treatment schemes have not yet been unequivocally established. Single-modality therapy does not have a major impact on long-term survival and combined-modality therapies are being further evaluated. However, the relative contributions of chemotherapy, radiotherapy and surgery have not been clearly determined at the present time. Moreover, the extent of resection and precise surgical procedure remain a highly debated topic. To better compare and combine results from different institutions and trials, uniform definitions of surgical procedures including extrapleural pneumonectomy and different forms of pleurectomy have recently been introduced. Due to the relatively higher morbidity and mortality of extrapleural pneumonectomy, there is currently a shift towards pleurectomy/decortication when a macroscopic complete resection of all tumour can be obtained by this procedure. In most recent trials, induction chemotherapy was administered to improve surgical resection rates but pathological complete responses are infrequently observed. The role of post-operative radiotherapy has to be further elucidated.Further treatment options that are currently explored include hyperthermic intrapleural chemotherapy, immunotherapy, gene therapy and photodynamic therapy. However, no randomised comparisons are available yet. @ERSpublications Treatment of malignant pleural mesothelioma remains controversial

show abstract

Section: Summary Of Current Guidelinesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multimodal management of malignant pleural mesothelioma: where are we today?

Schil

Opitz²,

Weder³

et al. 2014

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Any invasive procedure should be planned such that port sites may be excised at the time of thoracotomy. Current consensus guidelines from the International Mesothelioma Interest Group recommend complete pre-treatment staging, including surgical sampling of mediastinal lymph nodes, CT and/or PET scan, and MRI [10].…”

Section: Current Practice and Controversymentioning

confidence: 99%

“…These outcomes have fueled the debate over surgery further with proponents on both sides. Several important and very limiting issues were identified upon examining the MARS I trial [10]. In particular, not all patients in the surgery arm actually underwent a definitive operation, and 3 patients in the chemotherapy only arm underwent surgery outside the study protocol.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

Martin¹,

Zwischenberger²,

Fabian³

2014

JCT

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a rare primary tumor rising from the pleura and is associated with exposure to asbestos fibers. Mesothelioma is a locally aggressive disease that usually presents at an advanced stage and has a median overall survival of 1 year. Treatment options rarely result in cure of disease and range from trimodality treatment, including chemotherapy, radiation, and surgery, to supportive care. In patients with limited local disease and good functional status, trimodality treatment with extra-pleural pneumonectomy, chemotherapy, and radiation is frequently employed. Best supportive care should be instituted for patients with metastatic disease and poor functional status. Palliative therapy focuses on control of pleural effusions with drainage techniques and pain with radiation therapy. Novel therapies are showing promise, including photodynamic therapy, immunotherapy, and molecular targeted therapy.

show abstract

A preclinical model to investigate the role of surgically‐induced inflammation in tumor responses to intraoperative photodynamic therapy

et al. 2018

View full text Add to dashboard Cite

The tumor incision model induces IL-6 release as is seen in the surgical setting, yet it avoids the limitations of surgical resection models. Potential mechanisms by which surgical induction of inflammation and IL-6 could alter the nature and efficacy of tumor response to PDT are reviewed. These include a wide spectrum of molecular and cellular mechanisms through which surgically-induced IL-6 could change the effectiveness of therapies that are combined with surgery. The tumor incision model can be employed for novel investigations of the effects of surgically-induced, acute inflammation on therapeutic response to PDT (or potentially other therapies). Lasers Surg. Med. 50:440-450, 2018. © 2018 Wiley Periodicals, Inc.

show abstract

The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: Meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass

Cited by 145 publications

References 4 publications

Multimodal management of malignant pleural mesothelioma: where are we today?

Multimodal management of malignant pleural mesothelioma: where are we today?

Malignant Pleural Mesothelioma: Treatment Options and Novel Therapies

A preclinical model to investigate the role of surgically‐induced inflammation in tumor responses to intraoperative photodynamic therapy

Contact Info

Product

Resources

About